Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
GO:004348719 | Esophagus | ESCC | regulation of RNA stability | 117/8552 | 170/18723 | 7.91e-10 | 1.94e-08 | 117 |
GO:0031330111 | Esophagus | ESCC | negative regulation of cellular catabolic process | 166/8552 | 262/18723 | 5.17e-09 | 1.08e-07 | 166 |
GO:190236916 | Esophagus | ESCC | negative regulation of RNA catabolic process | 46/8552 | 75/18723 | 4.54e-03 | 1.78e-02 | 46 |
GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:003465511 | Liver | Cirrhotic | nucleobase-containing compound catabolic process | 171/4634 | 407/18723 | 9.07e-15 | 9.33e-13 | 171 |
GO:000640111 | Liver | Cirrhotic | RNA catabolic process | 126/4634 | 278/18723 | 4.64e-14 | 4.10e-12 | 126 |
GO:000989512 | Liver | Cirrhotic | negative regulation of catabolic process | 121/4634 | 320/18723 | 1.21e-07 | 3.39e-06 | 121 |
GO:004348711 | Liver | Cirrhotic | regulation of RNA stability | 73/4634 | 170/18723 | 1.44e-07 | 3.87e-06 | 73 |
GO:003133012 | Liver | Cirrhotic | negative regulation of cellular catabolic process | 101/4634 | 262/18723 | 4.57e-07 | 1.05e-05 | 101 |
GO:190236911 | Liver | Cirrhotic | negative regulation of RNA catabolic process | 29/4634 | 75/18723 | 5.24e-03 | 2.69e-02 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC17 | SNV | Missense_Mutation | | c.617N>C | p.Arg206Thr | p.R206T | | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.634) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC17 | SNV | Missense_Mutation | novel | c.323N>G | p.Ser108Cys | p.S108C | | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC17 | SNV | Missense_Mutation | novel | c.214T>C | p.Ser72Pro | p.S72P | | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZCCHC17 | SNV | Missense_Mutation | rs762726112 | c.203N>A | p.Arg68Gln | p.R68Q | | protein_coding | tolerated(0.33) | benign(0.024) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
ZCCHC17 | SNV | Missense_Mutation | novel | c.782N>G | p.His261Arg | p.H261R | | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZCCHC17 | SNV | Missense_Mutation | | c.226N>C | p.Val76Leu | p.V76L | | protein_coding | tolerated(0.08) | possibly_damaging(0.749) | TCGA-A5-A0GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCCHC17 | SNV | Missense_Mutation | rs762726112 | c.203N>A | p.Arg68Gln | p.R68Q | | protein_coding | tolerated(0.33) | benign(0.024) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ZCCHC17 | SNV | Missense_Mutation | rs762726112 | c.203N>A | p.Arg68Gln | p.R68Q | | protein_coding | tolerated(0.33) | benign(0.024) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZCCHC17 | SNV | Missense_Mutation | novel | c.329N>C | p.Lys110Thr | p.K110T | | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCCHC17 | SNV | Missense_Mutation | rs776735412 | c.194N>C | p.Leu65Pro | p.L65P | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |